Research | Page 13 of 22

JDRF Research Summit: Toward a Cure and Better Living with Type 1 Diabetes

On Feb. 18 I moderated the JDRF Capitol Chapter’s second annual Research Summit on Type 1 Diabetes...

Study Suggests Link Between Type 2 Diabetes and H. Pylori Bacteria

The presence of gastric H. pylori bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c) and type 2 diabetes, according to a study in the Journal of Infectious Diseases. Yu Chen, PhD, and Martin Blaser, MD, at NYU School of Medicine, part of NYU Langone Medical Center...

Gut Cells of Mice Transformed into Insulin-Producers

The goal of a therapy for type 1 diabetes is restoration of regulated insulin secretion. A newly published study, conducted by Chutima Talchai, PhD, and Domenico Accili, MD, professor of medicine at Columbia University Medical Center...

Type 1 Diabetes Study Highlights Interaction between Beta Cells and the Immune System

A new JDRF-funded study shows that many of the genes known to play a role in type 1 diabetes (T1D) are expressed in pancreatic beta cells, suggesting that the cell responsible for producing insulin may be playing a part in its own destruction to lead to T1D....

Beta Cells May Function Years After Type 1 Diabetes Diagnosis

A study conducted at Massachusetts General Hospital (MGH) has found that insulin production may persist for decades after the onset of type 1 diabetes. In the study, led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, blood samples from 182 individuals with type 1 diabetes were evaluated

Towards a Diabetes Cure: Beta Cell Updates from the PDRC Symposium

Finding a new and plentiful source of insulin production that works naturally within the body is one half of a cure for diabetes...

Diapep277: Slowing the Progression of Type 1 Diabetes

Diapep277 was discovered in 1990 by Professor Irun Cohen and his team at the Weizmann Institute's Department of Immunology...

Osiris Provides Update on Stem Cell Trial for Type 1 Diabetes

One year after Osiris Therapeutics in partnership with JDRF started the Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in newly diagnosed type 1 diabetes patients, the company has released a statement providing an update on this groundbreaking trial. This first-of-its kind trial is...